David A. Cooper

Statistics

Publications

Citations

H-Index

Active since

1965

Affiliations

National Centre for Clinical Research on Emerging Drugs(Current)

UNSW Sydney

HIV Netherlands Australia Thailand Research Collaboration

Chulalongkorn University

St Vincent's Hospital Sydney

David A. Cooper is an author at National Centre for Clinical Research on Emerging Drugs specializing in antiretroviral therapy, antiviral therapy, and pharmacotherapy.

ORCID

Publications per year

1965–2019

Publications

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, David A. Cooper, Princy Kumar et al. · New England Journal of Medicine · 2008 · 686 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Adriano Lazzarin, Bonaventura Clotet, David A. Cooper et al. · New England Journal of Medicine · 2003 · 653 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease

Sven A. Danner, Andrew Carr, John M. Leonard et al. · New England Journal of Medicine · 1995 · 573 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

David A. Cooper, Roy T. Steigbigel, José M. Gatell et al. · New England Journal of Medicine · 2008 · 507 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +14

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

1–5 of 94